The direct cost of care for psoriasis and psoriatic arthritis in the United States

被引:153
作者
Javitz, HS
Ward, MM
Farber, E
Nail, L
Vallow, SG
机构
[1] SRI Int, Hlth Sci Ctr, Menlo Pk, CA 94025 USA
[2] Univ Iowa, Dept Hlth Management & Policy, Iowa City, IA 52242 USA
[3] Psoriasis Res Ctr, Palo Alto, CA USA
[4] Stanford Univ, Palo Alto, CA 94304 USA
[5] SmithKline Beecham, Collegeville, PA USA
关键词
D O I
10.1067/mjd.2002.119669
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background.: Relatively little information is available in the literature concerning the cost of psoriasis in the United States, and much of that information is out of date. Objective: The present analyses estimate the direct cost of medical care for psoriasis (including psoriatic arthritis) from a societal perspective among adults in the United States. Method and Data: The costs of hospitalizations, outpatient and physician office visits, prescription and over-the-counter (OTC) medications, and medical procedures were estimated from the literature, analysis of publicly available health databases (Health and Nutrition Examination Survey, National Hospital Discharge Survey, Medicare Public Use Files, National Ambulatory Medical Care Survey, and the National Hospital Ambulatory Medical Care Survey), and analysis of privately available health databases (United Health Care/Diversified Pharmaceutical Services, the Medstat Group diagnosis-related group guide, and the: National Disease and Therapeutic Index). Costs were expressed as of 1997 by using Medicare and health maintenance organization reimbursement rates and wholesale drug costs. Costs of OTC medications were derived by adjusting a previous estimate in the literature for inflation in over-the-counter drugs and population increases. Results: The cost of illness for the approximately 1.4 million individuals with clinically significant disease is substantial-approximately $30.5 million for hospitalizations, $86.6 million for outpatient physician visits, $27.4 million for photochemotherapy, $147.9 million for dermatologic prescription drugs, and $357.2 million for OTC drugs, for a total direct cost of $649.6 million. Conclusion: Cost estimates from this study are substantially less than those found in previous studies ($1.09 billion and $4.32 billion after adjustment of estimates in the literature for medical inflation and population increases). This appears to be principally a result of decreases in hospitalization rates since 1979 and the valuation methodology per unit of medical services (with prior studies using "list" prices and the current study using reimbursement rates).
引用
收藏
页码:850 / 860
页数:11
相关论文
共 15 条
[1]   The magnitude of skin disease in the United States [J].
Fleischer, AB ;
Feldman, SR ;
Rapp, SR .
DERMATOLOGIC CLINICS, 2000, 18 (02) :XV-+
[2]   TRIVIAL OR TERRIBLE - THE PSYCHOSOCIAL IMPACT OF PSORIASIS [J].
FRIED, RG ;
FRIEDMAN, S ;
PARADIS, C ;
HATCH, M ;
LYNFIELD, Y ;
DUNCANSON, C ;
SHALITA, A .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 1995, 34 (02) :101-105
[3]   PREVALENCE, MORBIDITY, AND COST OF DERMATOLOGIC DISEASES [J].
JOHNSON, ML ;
JOHNSON, KG ;
ENGEL, A .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1984, 11 (05) :930-936
[4]  
JOHNSON MLT, 1978, VITAL HLTH STAT, V11, P212
[5]   Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment [J].
Koo, J .
DERMATOLOGIC CLINICS, 1996, 14 (03) :485-&
[6]  
KRANING KK, 1979, J INVEST DERMATOL, V73, P402
[7]   PSORIASIS [J].
KRUEGER, GG ;
BERGSTRESSER, PR ;
LOWE, NJ ;
VOORHEES, JJ ;
WEINSTEIN, GD .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1984, 11 (05) :937-947
[8]  
*MEDST GROUP, MEDST DRG GUID
[9]  
ROENIGK HH, 1991, PSORIASIS, P213
[10]   LONG-TERM USE OF PSORALENS AND ULTRAVIOLET-A FOR PSORIASIS - EVIDENCE FOR EFFICACY AND COST SAVINGS [J].
STERN, RS .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1986, 14 (03) :520-526